UK Supreme Court Ruling Favors Lilly

Lilly plans to present trial results at scientific meetings and publications this year and in 2016.

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

The UK Supreme Court has ruled in favor of Indianapolis-based Eli Lilly and Co. (NYSE: LLY) in a case relating to alternative salt forms of lung cancer treatment Alimta. The ruling suggests the products from generics manufacturer Actavis infringe on Lilly patents in the UK, France, Italy and Spain.

"While we do not yet know the court’s reasoning," said Lilly Senior Vice President Michael Harrington, "we are pleased with the UK Supreme Court’s key conclusions that confirm the Alimta vitamin regimen patent would be infringed by these generic pemetrexed products in the UK, France, Italy and Spain prior to June 2021."

He says the protection of intellectual property rights provides assurances "that help support the development of the next generation of innovative medicines to treat unmet medical needs."

The court is expected to hand down the full judgment on Wednesday.